MK-7418 - MK7418 - MK 7418 - KW-3902 - KW 3902 - rolofylline
All results are NS for efficacy
treatment success 0.92 [0.78; 1.09]
daily intravenous rolofylline (30 mg) for up to 3 days (n=-9)
vs.
placebo (n=-9)
double-blind
Parallel groups
Sample size: -9/-9
Primary endpoint: treatment success
FU duration: 3 days (60 days)
(n=-9)
Primary endpoint:
FU duration: